Navigation Links
JCI online early table of contents: Jan. 4, 2011

EDITOR'S PICK: Going bald without hair follicle progenitors

Androgenetic alopecia (AGA) is a frequent form of hair loss in both men and women. However, it is more common in men, in whom it is also known as male-pattern baldness. Through the analysis of bald and non-bald scalp samples from men with AGA, a team of researchers, led by George Cotsarelis, at the University of Pennsylvania School of Medicine, Philadelphia, has gained new insight into the underlying causes of AGA. Specifically, the data indicate that a defect in the conversion of hair follicle stem cells to progenitor cells has an important role in AGA. The authors therefore suggest that further studies defining the signals responsible for the transition of stem cells to progenitor cells could provide new therapeutic targets for the treatment of AGA.

TITLE: Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells

George Cotsarelis
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: 215.898.9967; Fax: 215.573.9102; E-mail:

View this article at:

EDITOR'S PICK: Dampening inflammation with aspirin

Inflammation is a protective response to invading microbes and tissue damage. Upon microbe clearance from the body or completion of wound healing, the inflammatory response must be dampened down. One set of molecules known to play a role in resolving the inflammatory response is the E-series resolvins. While analyzing the blood of several individuals to investigate the pathway by which E-series resolvins are generated, Charles Serhan and colleagues, at Harvard Medical School, Boston, identified a new 18S E-series resolvin. Importantly, the new resolvin reduced levels of pro-inflammatory molecules and cells in a mouse model of inflammation caused by the bacterium E. coli. Further, as the new resolvin could be generated from aspirin, the authors suggest that this molecule could contribute to the beneficial effects of aspirin.

TITLE: Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation

Charles N. Serhan
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Phone: 617.525.5001; Fax: 617.525.5017; E-mail:

View this article at:

VACCINE DESIGN: How to keep fungi at bay

Infections with fungi that initially start at one site (often the lung) and then spread to other organs in the body are known as systemic fungal infections. As rates of such infections have increased dramatically in recent years, researchers are keen on developing vaccines against these invasive microbes. A team of researchers, led by Marcel Wthrich, at the University of Wisconsin, Madison, has now generated data in mice that provide insight into the type of immune response that such vaccines need to generate.

In North America, the three main fungi that cause systemic fungal infections are Coccidioides posadasii, Histoplasma capsulatum, and Blastomyces dermatitidis. In the study, immune cells known as Th17 cells were found to be sufficient for vaccine-induced protection against lethal lung infection with Blastomyces dermatitidis in mice. Further, vaccine-induced Th17 cells were necessary and sufficient to protect mice against all three of the fungi linked to the majority of cases of systemic fungal infection in North America. The authors therefore suggest that vaccines designed to prevent systemic fungal infections in humans should be designed to induce Th17 cells.

TITLE: Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice

Marcel Wthrich
University of Wisconsin, Madison, Wisconsin, USA.
Phone: 608.262.7703; Fax: 608.262.8418; E-mail:

View this article at:

IMMUNOLOGY: TRACking immune deficiency

Impaired functioning of the immune system can be an inherited condition. Mutations in any one of a large number of genes involved in immune cell function can cause such disorders. A team of researchers, led by Eammon Maher, at the University of Birmingham School of Medicine, United Kingdom, has now identified another gene that can be added to the list: TRAC. Individuals with mutations in this gene exhibited autoimmunity (a condition in which the immune system turns on cells and/or tissues of the patient's own body) and increased susceptibility to certain infections. However, they surprisingly were protected from many infections, indicting that the TRAC mutations lead to only a partial immunodeficiency.

TITLE: Mutation in the TCR-alpha subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCR-alpha-beta+ T cells

Eamonn R. Maher
University of Birmingham School of Medicine, Birmingham, United Kingdom.
Phone: 44.121.627.2741; Fax: 44.121.414.2538; E-mail:

View this article at:

INFLAMMATION: New point of control for inflammation: the soluble factor leukotriene B4

Inappropriate inflammation is central to many diseases, including asthma, autoimmune disease, and atherosclerosis (often known as hardening of the arteries). Signaling through several sets of cell surface molecules on immune cells known as macrophages is a key driver of inflammation. In particular, signaling through proteins that rely on the adaptor protein MyD88. A team of researchers, led by Marc Peters-Golden and Carlos Serezani, at the University of Michigan Health System, Ann Arbor, has now shown that mouse macrophage inflammatory responses dependent on MyD88 are reduced in the absence of signals triggered by the molecule leukotriene B4 (LTB4). These data have clinical importance, as they suggest that inhibitors of LTB4 generation and or antagonists of the molecule to which it binds might provide a new therapeutic approach to dampening inflammatory disease.

TITLE: Leukotriene B4 amplifies NF-kappa-B activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression

Marc Peters-Golden
University of Michigan Health System, Ann Arbor, Michigan, USA.
Phone: 734.763.9077; Fax: 734.764.4556; E-mail:

Carlos H. Serezani
University of Michigan Health System, Ann Arbor, Michigan, USA.
Phone: 734.615.5523; Fax: 734.764.4556; E-mail:

View this article at:

NEUROBIOLOGY: New link between distinct neurological diseases

Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig's disease) and frontotemporal lobar degeneration (FTLD) are clinically quite distinct, although a few patients have some overlapping symptoms. However, both conditions are characterized by aggregates that contain the protein TDP-43 in the cytoplasm (the jelly-like substance that fills the cell) of nerve cells in the brain and spinal cord. Surprisingly, Virginia Lee and colleagues, at the University of Pennsylvania School of Medicine, Philadelphia, have now determined, using mice expressing either normal human TDP-43 or a mutant form of human TDP-43 that localized to the cytoplasm rather than the nucleus (the normal location for the protein), that the presence of TDP-43 cytoplasmic aggregates do not correlate with nerve cell death. Rather, nerve cell death correlated with loss of mouse TDP-43 in the nucleus, which led to profound alterations in gene expression. These data provide new insight into the link between TDP-43 and neurological disease.

TITLE: Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice

Virginia M.-Y. Lee
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: 215.662.6427; Fax: 215.349.5909; E-mail:

View this article at:

VIROLOGY: The protein A20 an impediment to HIV immunity

Preventing and/or containing HIV transmission requires immune responses throughout the body (i.e., systemic immune responses) and at the site of infection (i.e., mucosal surfaces such as the lining of the vagina). Ideal HIV vaccines should activate both of these immune responses, but approaches currently under development rarely do. A team of researchers, led by Si-Yi Chen and Xue Huang, has now found that downregulating expression of the protein A20 on immune cells known as DCs enhances their ability to induce both mucosal and systemic immune responses to HIV proteins in mice. The authors suggest that although further preclinical studies are necessary, these data might help researchers develop an efficient HIV vaccination strategy.

TITLE: Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells

Si-Yi Chen
University of Southern California, Los Angeles, California, USA.
Phone: 323.442.7727; Fax: 323.442.7729; E-mail:

Xue F. Huang
University of Southern California, Los Angeles, California, USA.
Phone: 323.442.7727; Fax: 323.442.7729; E-mail:

View this article at:


Contact: Karen Honey
Journal of Clinical Investigation

Related biology news :

1. TGen spin-off MedTrust Online enables cancer doctors to quickly obtain best-available information
2. Personalized medicine: Innovative online journal leads the way
3. Latin American Science Initiative Puts Tropical Rainforest Diversity Online
4. Smithsonian puts tropical Eastern-Pacific shore fishes online
5. Smithsonian puts tropical eastern Pacific shore fishes online
6. Powerful online tool for protein analysis provided pro bono by Stanford geneticist
7. New online report on massive jellyfish swarms released
8. JCI online early table of contents: Jan. 19, 2009
9. Online collaboration identifies bacteria
10. Free online toolkit provides standard measures for genome and population studies
11. K-State plant pathologists develop online teaching modules used globally
Post Your Comments:
(Date:10/5/2015)... , October 5, 2015 ... update for NXT-ID, Inc. (NASDAQ: NXTD ), a ... market. --> ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... SoundView Technology Group ( ) releases ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... Carolina (PRWEB) , ... October 12, 2015 , ... Spirax ... announce the release of the CSM-C 600 compact clean steam generator . ... steam that meets the requirements of HTM2031, HTM2010, and EN285 standards. The CMS-C ...
(Date:10/12/2015)... de octubre de 2015 El 8 de ... un récord en el congreso con su declaración acerca ... International Plasma Awareness Week (IPAW), que se celebrará del ... por la Plasma Protein Therapeutics Association (PPTA) ... , Aumentar la concienciación mundial acerca de la ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
(Date:10/10/2015)... ANNAPOLIS, Maryland , le 10 octobre 2015 ... (D-CA) a intégré dans le Registre du Congrès ... internationale annuelle pour la sensibilisation autour du plasma ... L,IPAW est sponsorisée par la Plasma Protein ... et vise à : , Sensibiliser ...
Breaking Biology Technology: